Founded in 2021, Geneva-based FluoSphera offers a 3D human-organ co-culture system that can house six to seven fluorescently coded tissue types in a single well, allowing researchers to evaluate drug efficacy and toxicity in one assay. The technology gives earlier, more human-relevant read-outs than traditional cell lines or animal studies and is already used by biotech and pharmaceutical partners, with strong traction in antibody-drug conjugate testing and a high-throughput screening collaboration with Revvity. FluoSphera claims its platform can save developers $100-500 million per molecule by cutting late-stage failures and time-to-market. The company aligns with regulatory shifts such as the FDA Modernisation Act 3.0 that encourage non-animal testing. Near-term plans include expanding commercial collaborations with pharma companies and CROs, bolstering business development, and enhancing AI-driven imaging analysis to scale the service. The firm also intends to extend its footprint across the US and EU while making initial inroads into Asia. Its recent CHF 1.15 million seed financing provides the capital to execute these growth initiatives.

Total raised

$2M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2026